USPTO Patent Applications - Pharma (A61K)

Depilatory Emulsion Containing Paclitaxel and Preparation Method

USPTO published patent application US20260090965A1 for a depilatory emulsion containing paclitaxel by inventor Ming Xia. The invention comprises 10-20% oil, 8-12% humectant, 4-6% emulsifiers, 8-12% paclitaxel solution, and auxiliary ingredients, designed to target hair follicles while preventing dermal absorption. A stepwise cooling and gradual emulsification method ensures stable emulsion formation.

Process for Making Aqueous Therapeutic Particles with Nanosized Water Clustering

USPTO published patent application US20260090957A1 for a process and apparatus for manufacturing aqueous therapeutic particles (AQTP) with stable exterior water clustering between 1-300 nanometers. The invention, assigned to a multi-inventor team, claims improved bioavailability for therapeutic compositions including CBD, PNC-27 peptides, pharmaceuticals, and nutraceuticals through a computer-controlled continuous manufacturing process.

Vital Pulp Therapy Using Bioactive Composites

USPTO published patent application US20260090960A1 by Imam Abdulrahman Bin Faisal University for a method of vital pulp therapy using a bioactive capping material. The invention comprises a mixture of glass ionomer cement (GIC) and potassium nitrate (KNO3) in 1-10 wt.% concentration with a solvent. The application was filed September 30, 2024.

Antiperspirant Cream Patent Application by Lume Deodorant LLC

The USPTO published patent application US20260090961A1 by Lume Deodorant, LLC for an antiperspirant cream composition containing water, an antiperspirant material, alpha-hydroxycarboxylic acid, an oil agent, and a structuring agent, with optional caffeine or xanthine derivatives. The application was filed on September 27, 2024, and names inventors Shannon Klingman, Stephanie Richmond, Rebecca Reynandez, and Nikita Bhatnagar. This is an informational publication of a patent application; no regulatory compliance obligations are created.

Hydrophobic Cellulose Powder for Cosmetic Applications

USPTO published patent application US20260090962A1 for surface-treated hydrophobic cellulose powder. The invention uses modified dextrin and/or modified amino acids to render cellulose powders hydrophobic, improving dispersibility, feel, and stability. The powders are intended for cosmetic applications including foundations, skin care, and hair care products.

Xanthommatin Color Additive for Food Beverage and Drug Compositions

USPTO published patent application US20260090963A1 by inventor Leila Deravi for xanthommatin as an edible color additive for food, beverage, and drug compositions at 0.01-0.5% wt concentration. The application covers substrates including foods, beverages, drinks, medications, and drug forms.

Composition Comprising Biosurfactant and Salicylic Acid

USPTO published L'OREAL's patent application for a skincare composition combining glycolipid biosurfactants with salicylic acid derivatives, cationic polymers, and clay for treating acne-prone skin. The application, filed September 30, 2024, covers formulations with water and glycerin solvents for topical use.

USPTO Patent Application for Compounds Targeting Pax3/Foxo1 Fusion Protein

The USPTO has published patent application US20260083724A1, filed by Georgetown University, for novel compounds designed to target the PAX3::FOXO1 fusion protein. These compounds aim to reduce protein levels and treat fusion-positive rhabdomyosarcoma.

Patent Application: Sigmari Ligand for Pancreatic Cancer Treatment

The USPTO has published a patent application (US20260083725A1) for a Sigmari Ligand for the treatment of pancreatic cancer. The application details a method involving a Sig-1R ligand to inhibit tumor growth and metastasis, filed on August 9, 2023.

Cancer Treatment Methods Using Tumor Treating Fields, Chemotherapy, and Anti-Fibrotic Agents

The USPTO has published a patent application detailing methods for treating cancer. The application describes compositions and systems involving the concurrent application of tumor treating fields, chemotherapeutic agents, and anti-fibrotic agents to reduce cancer cell viability and tumor growth.

Biopolymers for Ophthalmic Use Patent Application

The USPTO has published a patent application (US20260083771A1) for biopolymers intended for ophthalmic use, filed by ExoPolymer, Inc. The application details biopolymers comprising repeating polysaccharide units, their preparations, ophthalmic compositions, and methods of use.

Patent Application for Fiber-Based Prebiotic Dietary Supplements

The USPTO has published a patent application (US20260083772A1) for powder compositions comprising fiber intended for use as a prebiotic dietary supplement. The application details therapeutic ingredients and manufacturing processes aimed at improving gut microbiome and overall gut health.

Pegylated Menaquinol Compositions and Treatment Methods Patent Application

The USPTO has published a patent application (US20260083773A1) for pegylated menaquinol compositions and methods of treatment. The application, filed on December 5, 2025, discloses isolated, stable, and biologically active pegylated menaquinol derivatives for treating various diseases.

Patent Application: Acetic Acid and Hypochlorous Acid Compositions for Skin Trauma Treatment

The USPTO has published a new patent application (US20260083774A1) detailing compositions containing hypochlorous acid and acetic acid for treating skin trauma and biofilms. The application was filed on September 22, 2025, and published on March 26, 2026.

Metal nanoparticle agglomerates for infection control and water purification

The USPTO has published a patent application detailing the use of metal nanoparticle agglomerates for infection control and water purification. The application describes antiseptic substrates and fluid formulations incorporating these agglomerates for topical or oral use, aiming to provide infection control against infective agents.

Patent Application: Cytotoxic Lymphocyte Activation and Expansion

The USPTO has published patent application US20260083776A1 concerning methods for activating and expanding cytotoxic lymphocytes with decreased exhaustion potential. The application details micropatterned surfaces and biofunctionalization techniques for cell expansion, potentially impacting future therapeutic development in oncology.

Patent Application: Childhood Atropine Formulation for Myopia Progression

The USPTO has published a patent application (US20260083720A1) filed by Vyluma Inc. for a storage-stable, low-dose atropine formulation (0.01%) intended to reduce myopia progression in children. The application details the formulation's unexpected effectiveness compared to a higher concentration.

Dosing regimen for treating PKU with piperidine inhibitor

The USPTO has published a new patent application (US20260083714A1) detailing a dosing regimen for treating phenylketonuria (PKU) using a piperidine inhibitor of SLC6A19 function. The application was filed on August 25, 2023, by inventors John Peter Throup and Heather Smith Blanchette.

Immunity Enhancing Composition with Amide Compound

The USPTO has published a patent application (US20260083715A1) for a composition containing a novel amide-based compound derived from amino acids. The composition is designed to enhance immunity by activating macrophage phagocytosis, aiding in the removal of pathogenic bacteria.

R-Trihexyphenidyl Patent for Movement Disorder Treatment

The USPTO has published a new patent application, US20260083716A1, filed by The Children's Mercy Hospital. The patent covers compositions and methods for treating movement disorders, such as dystonia, using high chiral purity R-trihexyphenidyl.

Deuterated Domperidone Formulations for Gastroparesis and Nausea

The USPTO has published a patent application (US20260083717A1) for deuterated domperidone formulations. These formulations are intended for treating gastroparesis, nausea, vomiting, and other related conditions. The application details specific excipient combinations for these pharmaceutical compositions.

Piperidine Urea Derivatives for Obesity Therapy Patent Application

The USPTO has published a patent application (US20260083718A1) filed by Astrizi Bio, Inc. The application describes piperidine urea derivatives for preventing, suppressing, or treating obesity, potentially in combination with GLP-1 receptor agonists.

USPTO Patent Application for Improving Sperm Quality

The USPTO has published a patent application (US20260083719A1) filed by The University of Adelaide for methods and products aimed at improving sperm quality. The application details the use of specific compounds, such as BGP-15, in assisted reproductive technologies.

Therapeutic Agent for ALS Inhibits Ferroptosis Using Tetrahydroquinoline Derivative

The USPTO has published a patent application (US20260083723A1) from Toray Industries, Inc. The application describes a therapeutic or preventive agent for amyotrophic lateral sclerosis (ALS) that inhibits ferroptosis, utilizing a tetrahydroquinoline derivative as the active ingredient. This filing details compositions and methods for treating ALS and inhibiting ferroptosis.

Patent for treating ocular autoimmune disorder comorbidities with roflumilast

The USPTO has published a new patent application (US20260083712A1) assigned to Iolyx Therapeutics, Inc. The patent describes methods for treating ocular comorbidities of autoimmune disorders, such as dry eye disease, using ophthalmic formulations of roflumilast. The application was filed on September 19, 2025.

USPTO Patent Application for Acute Migraine Treatment with Ubrogepant

The USPTO has published a new patent application (US20260083710A1) detailing methods for the acute treatment of migraine using the drug ubrogepant. The application includes specific claims related to treatment in patients with hepatic or renal impairment and those concurrently taking certain CYP3A4 modulators or BCRP/P-gp inhibitors.

Patent Application: Combination Pharmacological Interventions for Sleep Apnea

The USPTO has published patent application US20260083709A1, detailing a novel pharmacological intervention for treating obstructive sleep apnea. The application, filed on December 3, 2025, describes pharmaceutical compositions involving a combination of a norepinephrine reuptake inhibitor, muscarinic receptor antagonist, and carbonic anhydrase inhibitor.

Novel LXR Modulators with Bicyclic Core for Treating Dyslipidemias

The USPTO has published a new patent application, US20260083704A1, detailing novel LXR modulators with a bicyclic core for treating dyslipidemias and related metabolic disorders. The application was filed on May 1, 2025, and published on March 26, 2026.

USPTO Patent Application for Transdermal Dexmedetomidine

The USPTO has published patent application US20260083705A1 for methods of using transdermal delivery patches containing dexmedetomidine to treat agitation. The application was filed on September 24, 2025, by inventors Wan-Ning Song and Gary G. Kay.

Patent Application: Methods for treating epilepsy using 5HT receptor agonists

The USPTO has published a new patent application (US20260083706A1) detailing methods for treating epilepsy using 5HT receptor agonists. The application was filed on May 29, 2025, by inventor Scott C. Baraban.

Tinostamustine for T-cell prolymphocytic leukemia treatment patent

The USPTO has published a patent application (US20260083707A1) for Purdue Pharma L.P. detailing the use of tinostamustine for treating T-cell prolymphocytic leukemia. The application was filed on July 28, 2025.

Patent Application: Compounds for Inhibiting IL-17

The USPTO has published a patent application (US20260083708A1) detailing compounds for inhibiting IL-17 activity. The application, filed on December 1, 2025, describes compounds and methods for treating inflammatory and autoimmune disorders.

Multilayered Microparticles for Controlled Release of Active Compounds

The USPTO has published a new patent application (US20260083713A1) detailing multilayered microparticles for controlled release of active compounds in liquid dosage forms. The application was filed on October 21, 2025, by inventors from Belgium.

Patent Application: Methods Treat/Prevent Protein Aggregation Diseases Using Sulfatase Inhibitor

The USPTO has published a new patent application (US20260083700A1) detailing methods for treating and/or preventing protein-aggregation diseases by administering a sulfatase inhibitor. The application was filed on September 26, 2025, by inventors Manuel J. Muñoz, Ángel M. Carrión, and Mercedes M. Pérez-Jiménez.

Patent Application for Suppressing Reflux-Induced Protein Adducts

The USPTO has published patent application US20260083686A1, filed on November 24, 2025, by Alexander Zaika and Sergey I Dikalov. The application details methods and compounds for suppressing the accumulation of reflux-induced protein adducts.

USPTO Patent Application for Lactation Reduction Compounds

The USPTO has published a patent application (US20260083687A1) for compounds intended for reducing lactation and improving health. The application, filed on April 14, 2023, lists specific disulfide, sulfide, trisulfide, sulfone, thiosulfinate, and thiosulfonate compounds as preferred embodiments. This represents a new patent filing, not a regulatory rule or guidance.

Skin Barrier Film System Patent Application

The USPTO has published a new patent application, US20260083684A1, for a skin barrier film system. The application details a system comprising a film layer, adhesive, impregnated treatment, and a removable layer, designed to accommodate patient physical attributes. The filing date was September 24, 2025.

Method Uses Monoterpene or Sesquiterpene to Permeabilize Blood Brain Barrier

The USPTO has published a patent application detailing a method for permeabilizing the blood-brain barrier using monoterpenes or sesquiterpenes. The application, assigned to the University of Southern California, describes a treatment for central nervous system cancers involving perillyl alcohol and CAR-T cells.

NACA Tablets Inhibit Vision Reduction in Usher Syndrome Patients

The USPTO has published a patent application (US20260083688A1) detailing compositions and methods for treating Usher syndrome associated retinitis pigmentosa using N-acetylcysteine amide (NACA) tablets. The application outlines specific dosages and claims to inhibit vision degradation and protect retinal sensitivity in patients.

Patent Application: Reversing Dexmedetomidine Sedation

The USPTO has published a patent application (US20260083689A1) detailing methods and compositions for reversing dexmedetomidine sedation using dextroamphetamine and/or lisdexamfetamine. The application was filed on October 7, 2025, by inventors Ken Solt, Oluwaseun Johnson-Akeju, and Emery N. Brown.

Patent Application for Dispersible Pharmaceutical Formulations

The USPTO has published patent application US20260083690A1 concerning dispersible pharmaceutical formulations of a specific chemical compound. The application details the composition and potential uses of these formulations.

Patent Application for Treating Disease with Dichlorphenamide

The USPTO has published a patent application (US20260083692A1) from Strongbridge Dublin Limited for methods of treating disease using dichlorphenamide in conjunction with an organic anion transporter-1 (OAT1) substrate. The application details methods for administering the compounds and monitoring patient response and toxicity.

Intranasal Pharmaceutical Composition for Migraine Treatment

The USPTO has published a patent application (US20260083693A1) for an intranasal pharmaceutical composition containing ibuprofen and ketoprofen for treating migraine and headaches. The application details a method for manufacturing preparations with a combination of these active ingredients at reduced dosages compared to oral administration.

Composition of L-leucine and fish oil for muscle health

The USPTO has published a patent application (US20260083694A1) for a composition comprising L-leucine and fish oil, intended for muscle health and the prevention of muscle mass and strength loss. The application was filed by ABIOGEN PHARMA S.P.A.

Patent Application: Composition for Mitigating Veisalgia and Nausea

The USPTO has published a patent application (US20260083695A1) for a composition designed to reduce veisalgia (hangover) symptoms and nausea. The application details an orally deliverable formulation containing dihydromyricetin, acetylcysteine, and specific antiemetics, with a filing date of September 10, 2025.

Gamma-hydroxybutyrate Formulations with Improved Pharmacokinetics

The USPTO has published a new patent application, US20260083696A1, detailing modified release formulations of gamma-hydroxybutyrate with improved dissolution and pharmacokinetic properties. The application was filed on October 1, 2025, by inventors Jordan Dubow, Claire Megret, Hervé Guillard, and Jean-François Dubuisson.

Patent Application: Composition for Controlling Aquatic Organism Infections

The USPTO has published a new patent application (US20260083697A1) from B. G. Negev Technologies and Applications Ltd. The application details a composition containing an esterified fatty acid for preventing or treating monogenean infections in aquatic organisms.

Patent Application: Synergistic Stimulation for Cystic Fibrosis Mucus Obstruction

The USPTO has published a new patent application (US20260083698A1) detailing methods for treating mucus obstruction in cystic fibrosis and other disorders. The application, filed on September 19, 2023, describes a combination therapy involving a b-adrenergic agonist or adenylate cyclase activator with a cholinergic agonist.

Patent Application for Psychoactive Medicines Treating Disorders

The USPTO has published patent application US20260083699A1 by Transcend Therapeutics, Inc. The application details psychoactive medicines, including 2C-B and cathinones, for treating psychiatric and neurological conditions. The filing date was December 4, 2025.

Patent Application for Inflammatory Condition Treatment Compositions

The USPTO has published a new patent application (US20260083701A1) for compositions and methods related to the treatment of inflammatory conditions. The application details compounds and formulations aimed at managing inflammation and associated symptoms like dryness, itching, and redness.